ACTRN12618001036202招募中不适用
A Two-Part Study to Assess the Effects of Ritonavir on PRN1008 Pharmacokinetics, and the Effects of PRN1008 on QTc Interval Compared to Placebo and Moxifloxacin in Healthy Participants
适应症
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 40
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 Years 至 55 Years（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)EUCTR2004-004774-85-LTBiogen Idec Inc160
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)EUCTR2004-004774-85-DEBiogen Idec Inc160
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)EUCTR2004-004774-85-CZBiogen Idec Inc160
进行中（未招募）
1 期
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12EUCTR2004-004774-85-GBBiogen Idec Inc160
进行中（未招募）
不适用
A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens - 102-12Relapsed (maximum of 5 relapses) or refractory, low-grade or follicular, CD20+, B-cell Non-Hodgkin’s Lymphoma (NHL)EUCTR2004-004774-85-SEBiogen Idec Inc160